TELA Bio to Participate in Upcoming JMP Securities Life Sciences Conference

MALVERN, Pa., June 14, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in the JMP Securities Life Sciences Conference.

TELA Bio's management is scheduled to present at the JMP Securities Life Sciences Conference on Wednesday, June 16, 2021 at 11:30 AM EDT. Interested parties can access the live and archived webcast at ir.telabio.com.

About TELA Bio, Inc.

TELA Bio Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The Company is committed to providing patients with advanced, economically effective biologic material repair solutions to minimize long-term exposure to permanent synthetic materials and improve clinical outcomes. TELA Bio's OviTex® and OviTex PRS Reinforced Tissue Matrix products are purposefully designed to address the shortcomings of existing reinforcement materials in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery. For more information, visit www.telabio.com.

Investor Contact
Greg Chodaczek
347-620-7010 
[email protected]

You May Also Be Interested In

• QNB Corp. Announces Exercise of Overallotment Option of 160,714 Shares of Common Stock
• Precore Gold Announces Up to C$6 Million Private Placement
• The Boston Beer Company Announces CFO Transition